SCHEMBL20178896

SCHEMBL20178896

O=C(O)c1ccc(C#Cc2cc(O)cc(C34CC5CC(CC(C5)C3)C4)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 7/20 0.48
RARB P10826 6/20 0.48
RARG P13631 6/20 0.48
HIF1A Q16665 3/20 0.45
EPAS1 Q99814 2/20 0.45
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
THRB P10828 1/20 0.44
RECQL P46063 1/20 0.44
NR2E1 Q9Y466 1/20 0.44
CYP3A4 P08684 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2709569 0.81 HIF1A (0.46) RARARARBRARGHIF1AEPAS1
SCHEMBL6378001 0.78 RARA (0.65) RARARARBRARGHIF1AEPAS1
SCHEMBL422261 0.75 NPC1 (0.56) RARARARBRARGHIF1AEPAS1
SCHEMBL2708795 0.75 HIF1A (0.49) HIF1AEPAS1MEN1KMT2AALDH1A1
SCHEMBL2707051 0.75 SERPINE1 (0.47) RARARARBRARGHIF1AEPAS1
SCHEMBL2707858 0.75 SERPINE1 (0.47) RARARARBRARGHIF1AEPAS1
SCHEMBL6770754 0.74 ALDH1A1 (0.46) HIF1AEPAS1MEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL2710121 0.74 NPC1 (0.54) RARARARBRARGHIF1AEPAS1
SCHEMBL25720237 0.73 MEN1 (0.45) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL8616987 0.72 RARA (0.65) RARARARBRARGMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10980778-B2 Methods for treating multiple osteochondroma (MO) Clementia Pharmaceuticals Inc. (CA) 2021-04-20 US disclosed
US-20190275005-A1 METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) Clementia Pharmaceuticals Inc. (CA) 2019-09-12 US disclosed
WO-2018090137-A1 METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) Clementia Pharmaceuticals Inc. (CA) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10980778-B2 Methods for treating multiple osteochondroma (MO) UTRN, VHL, SOST RARA 1990/4885RARB 1620/4885RARG 1720/4885
US-20190275005-A1 METHODS FOR TREATING MULTIPLE OSTEOCHONDROMA (MO) UTRN, VHL, SOST RARA 1990/4885RARB 1620/4885RARG 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.